Literature DB >> 16394010

A potent adjuvant monophosphoryl lipid A triggers various immune responses, but not secretion of IL-1beta or activation of caspase-1.

Kazuo Okemoto1, Kiyoshi Kawasaki, Kentaro Hanada, Masami Miura, Masahiro Nishijima.   

Abstract

Lipid A, the membrane anchor portion of LPS, is responsible for the endotoxin activity of LPS and induces many inflammatory responses in macrophages. Monophosphoryl lipid A (MPL), a lipid A derivative lacking a phosphate residue, induces potent immune responses with low toxicity. To elucidate the mechanism underlying the low toxicity of MPL, we examined the effects of MPL on the secretion of proinflammatory cytokines by mouse peritoneal macrophages, a murine macrophage-like cell line (RAW 264.7), and a human macrophage-like cell line (THP-1). MPL enhanced the secretion of TNF-alpha, but not that of IL-1beta, whereas Escherichia coli-type lipid A (natural source-derived and chemically synthesized lipid A) enhanced the secretion of both cytokines. Although MPL enhanced the levels of IL-1beta mRNA and IL-1beta precursor protein to levels similar to those induced by lipid A, IL-1beta precursor processing in MPL-treated cells was much lower than that in E. coli-type lipid A-treated ones. Moreover, MPL, unlike E. coli-type lipid A, failed to induce activation of caspase-1, which catalyzes IL-1beta precursor processing. These results suggest that an immune response without activation of caspase-1 or secretion of IL-1beta results in the low toxicity of this adjuvant.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16394010     DOI: 10.4049/jimmunol.176.2.1203

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  33 in total

Review 1.  Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant?

Authors:  Robert S Munford
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

2.  The requirement of CD80, CD86, and ICAM-1 on the ability of adjuvant formulations to potentiate antibody responses to a Plasmodium falciparum blood-stage vaccine.

Authors:  George Hui; Caryn Hashimoto
Journal:  Vaccine       Date:  2007-10-26       Impact factor: 3.641

3.  Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo.

Authors:  Pernille Nordly; Else Marie Agger; Peter Andersen; Hanne Mørck Nielsen; Camilla Foged
Journal:  Pharm Res       Date:  2010-11-02       Impact factor: 4.200

4.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

5.  Burkholderia pseudomallei type III secretion system mutants exhibit delayed vacuolar escape phenotypes in RAW 264.7 murine macrophages.

Authors:  Mary N Burtnick; Paul J Brett; Vinod Nair; Jonathan M Warawa; Donald E Woods; Frank C Gherardini
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

6.  Discovery and Structure-Activity Relationships of the Neoseptins: A New Class of Toll-like Receptor-4 (TLR4) Agonists.

Authors:  Matthew D Morin; Ying Wang; Brian T Jones; Lijing Su; Murali M R P Surakattula; Michael Berger; Hua Huang; Elliot K Beutler; Hong Zhang; Bruce Beutler; Dale L Boger
Journal:  J Med Chem       Date:  2016-04-25       Impact factor: 7.446

Review 7.  Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues.

Authors:  Aileen F B White; Alexei V Demchenko
Journal:  Adv Carbohydr Chem Biochem       Date:  2014       Impact factor: 12.200

Review 8.  Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant.

Authors:  C R Casella; T C Mitchell
Journal:  Cell Mol Life Sci       Date:  2008-10       Impact factor: 9.261

9.  Lipopolysaccharide analogs improve efficacy of acellular pertussis vaccine and reduce type I hypersensitivity in mice.

Authors:  Jeroen Geurtsen; H Alexander Banus; Eric R Gremmer; Henke Ferguson; Liset J J de la Fonteyne-Blankestijn; Jolanda P Vermeulen; Jan A M A Dormans; Jan Tommassen; Peter van der Ley; Frits R Mooi; Rob J Vandebriel
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

10.  Using distinct molecular signatures of human monocytes and dendritic cells to predict adjuvant activity and pyrogenicity of TLR agonists.

Authors:  Richard Kenmoe Kamgang; Inês Ramos; Lurdes Rodrigues Duarte; Mascia Ghielmetti; Marina Freudenberg; Clemens Dahinden; Elisabetta Padovan
Journal:  Med Microbiol Immunol       Date:  2008-02-19       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.